HUP9802314A2 - Pure 3r-3'r stereoisomer of zeaxanthin for treating macular degeneration in humans - Google Patents

Pure 3r-3'r stereoisomer of zeaxanthin for treating macular degeneration in humans

Info

Publication number
HUP9802314A2
HUP9802314A2 HU9802314A HUP9802314A HUP9802314A2 HU P9802314 A2 HUP9802314 A2 HU P9802314A2 HU 9802314 A HU9802314 A HU 9802314A HU P9802314 A HUP9802314 A HU P9802314A HU P9802314 A2 HUP9802314 A2 HU P9802314A2
Authority
HU
Hungary
Prior art keywords
zeaxanthin
humans
macular degeneration
pure
stereoisomer
Prior art date
Application number
HU9802314A
Other languages
Hungarian (hu)
Inventor
Kevin M. Garnett
Dennis L. Gierhart
Luis H. Guerra-Santos
Original Assignee
Appleid Food Biotechnology, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/551,153 external-priority patent/US5827652A/en
Priority claimed from US08/551,166 external-priority patent/US5854015A/en
Application filed by Appleid Food Biotechnology, Inc. filed Critical Appleid Food Biotechnology, Inc.
Publication of HUP9802314A2 publication Critical patent/HUP9802314A2/en
Publication of HUP9802314A3 publication Critical patent/HUP9802314A3/en
Publication of HU223208B1 publication Critical patent/HU223208B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Botany (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A találmány a zeaxantinnak nevezett karőtinőid 3R-3' Rsztereőizőmerjének tiszta főrmában való előállítására és gyógyszerkéntvagy tápanyagkiegészítőként emberben a retina kárősődását őkőzómakűláris degeneráció kezelésére történik, az alkalmazáshőz tisztítőttés részlegesen tisztítőtt zeaxantin is használható. ŕThe invention is for the production of the 3R-3' Rstereostimulatory compound called zeaxanthin in its pure form and as a medicine or nutritional supplement for the treatment of macular degeneration, which is a damage to the retina in humans, partially purified zeaxanthin can also be used. ŕ

HU9802314A 1995-10-31 1996-10-30 Use of pure 3r-3'r stereoisomer of zeaxanthin for preparation of pharmaceuticals or foodstoffs for treating macular degeneration in humans HU223208B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/551,153 US5827652A (en) 1995-10-31 1995-10-31 Zeaxanthin formulations for human ingestion
US08/551,166 US5854015A (en) 1995-10-31 1995-10-31 Method of making pure 3R-3'R stereoisomer of zeaxanthin for human ingestion
PCT/US1996/017563 WO1997016175A1 (en) 1995-10-31 1996-10-30 Pure 3r-3'r stereoisomer of zeaxanthin for treating macular degeneration in humans

Publications (3)

Publication Number Publication Date
HUP9802314A2 true HUP9802314A2 (en) 1999-04-28
HUP9802314A3 HUP9802314A3 (en) 1999-05-28
HU223208B1 HU223208B1 (en) 2004-03-29

Family

ID=27069666

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9802314A HU223208B1 (en) 1995-10-31 1996-10-30 Use of pure 3r-3'r stereoisomer of zeaxanthin for preparation of pharmaceuticals or foodstoffs for treating macular degeneration in humans

Country Status (14)

Country Link
JP (1) JPH10512594A (en)
KR (1) KR100570251B1 (en)
CN (1) CN1104235C (en)
AR (1) AR004245A1 (en)
AU (1) AU710634B2 (en)
BR (1) BR9611488A (en)
CZ (1) CZ297575B6 (en)
FI (1) FI980947A (en)
HU (1) HU223208B1 (en)
NO (1) NO981698L (en)
PL (1) PL185465B1 (en)
RU (1) RU2197958C2 (en)
WO (1) WO1997016175A1 (en)
ZA (1) ZA969139B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8088363B2 (en) * 2002-10-28 2012-01-03 Zeavision Llc Protection against sunburn and skin problems with orally-ingested high-dosage zeaxanthin
GB0501365D0 (en) * 2005-01-21 2005-03-02 Promar As Compositions
WO2006086706A2 (en) * 2005-02-11 2006-08-17 Kalamazoo Holdings, Inc. A capsicum variety exhibiting a hyper-accumulation of zeaxanthin and products derived therefrom
US8592662B2 (en) 2005-02-11 2013-11-26 Kalamazoo Holdings, Inc. Capsicum variety exhibiting a hyper-accumulation of zeaxanthin and products derived therefrom

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US308759A (en) * 1884-12-02 Curling hat-brims and machine therefor
EP0534955B1 (en) * 1989-08-30 1997-05-28 Applied Food Biotechnology, Inc. Process for the production of a zeaxanthin-containing composition using a microorganism of the species Flavobacterium multivorum
US5310764A (en) * 1992-05-08 1994-05-10 Steven Baranowitz Treatment of age related macular degeneration with beta-carotene

Also Published As

Publication number Publication date
MX9605248A (en) 1998-06-30
AR004245A1 (en) 1998-11-04
AU710634B2 (en) 1999-09-23
FI980947A0 (en) 1996-10-30
CZ130998A3 (en) 1998-07-15
HU223208B1 (en) 2004-03-29
ZA969139B (en) 1997-09-25
CZ297575B6 (en) 2007-02-07
KR19990067180A (en) 1999-08-16
HUP9802314A3 (en) 1999-05-28
JPH10512594A (en) 1998-12-02
NO981698D0 (en) 1998-04-16
PL326558A1 (en) 1998-09-28
CN1104235C (en) 2003-04-02
FI980947A (en) 1998-04-29
AU7050196A (en) 1997-05-08
BR9611488A (en) 1999-01-19
KR100570251B1 (en) 2006-06-21
NO981698L (en) 1998-06-08
CN1201388A (en) 1998-12-09
PL185465B1 (en) 2003-05-30
RU2197958C2 (en) 2003-02-10
WO1997016175A1 (en) 1997-05-09

Similar Documents

Publication Publication Date Title
EP1225168B8 (en) Prostaglandin-F-2 alpha derivative for the treatment of glaucoma or ocular hypertension
AU6586896A (en) Fatty acid treatment
CA2272584A1 (en) Novel substituted pyrazole derivatives for the treatment of cardiocirculatory diseases
MX9702349A (en) Use of 9-deoxy prostaglandin derivatives to treat glaucoma.
WO2003032994A3 (en) Novel tri-substituted pyrimidines, method for production and use thereof as medicament
MX9604378A (en) Substituted quinoline-2-carboxylic acid amides, their preparation and their use as medicaments, as well as intermediate products thereof.
ATE116848T1 (en) USE OF BACLOFEN IN THE PRODUCTION OF MEDICINAL PRODUCTS FOR THE TREATMENT OF ANGINA PECTORIS.
ATE234615T1 (en) USE OF ACETYLCYSTONE IN THE PRODUCTION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF CHRONIC ULCERS
PL310474A1 (en) Application of rilusole in treating neuro-aids diseases
HUP9900654A1 (en) Preparations stimulating nail growth, process for their preparation and use of them
HUP9802121A2 (en) Imidazoline derivatives, process for producing them and pharmaceutical compositions containing them
CA2157836A1 (en) L-carnitine salt and cosmetic and pharmaceutical compositions containing same for treating dermatoses
DE3864691D1 (en) THIAZOLIDIN-4-CARBONIC ACID DERIVATIVE, ITS PRODUCTION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN IT.
WO2002100836A3 (en) Compounds, compositions and methods for modulating beta-amyloid production
BG105275A (en) Tan-1057 derivatives
HUP9802314A2 (en) Pure 3r-3'r stereoisomer of zeaxanthin for treating macular degeneration in humans
DK0700897T3 (en) L-carnitine salt and cosmetic and pharmaceutical preparations containing the same for the treatment of skin diseases
EP0273310A3 (en) 5-aryl-3h-1,2,4-triazol-3-ones and their use as anticonvulsants
IE870577L (en) Topical amide preparation
ATE192650T1 (en) USE OF EFAROXAN AND ITS DERIVATIVES FOR THE PRODUCTION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF PARKINSON'S DISEASE
TW232014B (en)
AU3406089A (en) Novel strobilurine derivatives, their preparation and their use
ATE270882T1 (en) 3R-3'R DIASTEREOISOMER OF ZEAXANTHIN FOR THE TREATMENT OF MACULA DEGENERATION
AU7230894A (en) Use of efaxoran and its derivatives for the production of drugs for treating neurodegenerative diseases
ATE6124T1 (en) PHARMACEUTICALS FOR THE LOCAL TREATMENT OF GLAUCOMA.

Legal Events

Date Code Title Description
HFG4 Patent granted, date of granting

Effective date: 20040216

MM4A Lapse of definitive patent protection due to non-payment of fees